Heart failure with normal pumping and fatty liver disease linked to metabolism: Two problems, one metabolic approach

Heart failure with preserved ejection fraction (HFpEF) has become the most common type of heart failure.

• HFpEF is primarily associated with chronic low-grade inflammation and metabolic disorders.
• The coexistence of HFpEF and metabolic dysfunction-associated steatotic liver disease (MASLD) complicates clinical management due to overlapping metabolic issues.
• Sodium-glucose cotransporter 2 inhibitors have demonstrated potential benefits in treating both HFpEF and MASLD.
• Glucagon-like peptide-1 receptor agonists are under investigation for their possible advantages in managing MASLD.
• A comprehensive approach that integrates metabolic and cardiovascular care may be crucial for improving patient outcomes.

Simplified